Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

The ph2b start in Q2 with the possibly concurrent NVS option exercise is the real and game changing catalyst.

As for the ph2a ad hoc analyses I doubt any of the patients is still on Emricasan , unless they are taking it on a compassionate basis. So I expect any subsequent analyses after the 6 months dosing, to show a disease rebound in most, if not all, of the patient (this may be a useful information itself)